Literature DB >> 18294633

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

Murat Toruner1, Edward V Loftus, W Scott Harmsen, Alan R Zinsmeister, Robert Orenstein, William J Sandborn, Jean-Frederic Colombel, Laurence J Egan.   

Abstract

BACKGROUND & AIMS: We sought to identify and quantify the clinical factors that were associated with opportunistic infections in inflammatory bowel disease patients.
METHODS: We identified 100 consecutive IBD patients with opportunistic infections. For each case, 2 matched IBD patients who did not have a history of opportunistic infection were selected as controls. Conditional logistic regression was used to assess associations between putative risk factors and opportunistic infections, presented as odds ratios (OR) and 95% confidence intervals (CIs).
RESULTS: In univariate analysis, use of corticosteroids (OR, 3.4; 95% CI, 1.8-6.2), azathioprine/6-mercaptopurine (OR, 3.1; 95% CI, 1.7-5.5), and infliximab (OR, 4.4; 95% CI, 1.2-17.1) were associated individually with significantly increased odds for opportunistic infection. Multivariate analysis indicated that use of any one of these drugs yielded an OR of 2.9 (95% CI, 1.5-5.3), whereas use of 2 or 3 of these drugs yielded an OR of 14.5 (95% CI, 4.9-43) for opportunistic infection. The relative risk of opportunistic infection was greatest in IBD patients seen at older than 50 years of age (OR, 3.0; 95% CI, 1.2-7.2, relative to those 24 years or younger). No patient died from opportunistic infection.
CONCLUSIONS: Immunosuppressive medications, especially when used in combination, and older age are associated with increased risk of opportunistic infections. The absolute risk of opportunistic infection in IBD patients remains to be determined, as does any potential benefit of any preventive strategy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18294633     DOI: 10.1053/j.gastro.2008.01.012

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  267 in total

Review 1.  Management of Ulcerative Colitis in the Elderly.

Authors:  Manish P Shrestha; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

2.  Predictors of aggressive inflammatory bowel disease.

Authors:  Andres J Yarur; Sebastian G Strobel; Amar R Deshpande; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

3.  Emerging data in the concomitant use of immunomodulators and biologic therapies.

Authors:  Gary R Lichtenstein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-07

4.  Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group.

Authors:  Miles P Sparrow; Peter M Irving; Leonard Baidoo; Brian Bressler; Adam S Cheifetz; Shane M Devlin; Laura E Harrell; Jennifer Jones; Patricia L Kozuch; Gil Y Melmed; Fernando S Velayos; Corey A Siegel
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-10

5.  Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model.

Authors:  Corey A Siegel; Samuel R G Finlayson; Bruce E Sands; Anna N A Tosteson
Journal:  Clin Gastroenterol Hepatol       Date:  2011-10-01       Impact factor: 11.382

6.  Tailoring the treatment to the individual in Crohn's disease.

Authors:  Edouard Louis; Jacques Belaiche; Catherine Reenaers
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

7.  Patient preferences for surgical versus medical therapy for ulcerative colitis.

Authors:  Meenakshi Bewtra; Vikram Kilambi; Angelyn O Fairchild; Corey A Siegel; James D Lewis; F Reed Johnson
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

Review 8.  A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population.

Authors:  David Kim; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

9.  Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Authors:  Fumiaki Ueno; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Matsuoka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-10-23       Impact factor: 7.527

Review 10.  Biologic therapy and surgery for crohn disease.

Authors:  E Carter Paulson
Journal:  Clin Colon Rectal Surg       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.